EUVIMEDOpdag EUVIMED
Systematische ÜbersichtMetaanalyseÜbersichtsarbeit

Metformin for COVID‐19: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Taimoor Tahir, Muhammad Abubakr Siddique iD, Khadija Ijaz, Hania Nadeem, Abdur Rehman, Sameen Khan, Amna Humayun Tarar, Lajwanti, Muhammad Ahmad Shujja Zafar, Fatima Raja, Uzair Jafar, Asma'a Munasar Ali Alsubari iD and 2 more

Reviews in Medical Virology · 2026

DOI: 10.1002/rmv.70172 ↗

At a glance

Systematische Übersicht in Reviews in Medical Virology, 2026. Written by Taimoor Tahir and 13 co-authors. Institution: Department of Medicine, Kuwait Teaching Hospital, Peshawar, Pakistan. Major MEDLINE topics: Metformin, COVID-19 Drug Treatment, Hypoglycemic Agents. 31 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Metformin has been shown to reduce hospitalisation and symptom duration among adults with COVID‐19, but the effect has not been studied. We conducted this meta‐analysis to assess the efficacy and safety of metformin in patients with COVID‐19. Randomized controlled trials (RCTs) comparing metformin with placebo in COVID‐19 were identified through major databases through November 2025. We performed statistical analyses using RevMan 5.4, employing the random‐effects model, along with Risk Ratio (RR) and Mean Difference (MD) as the effect measures. Our meta‐analysis of four RCTs showed that metformin did not significantly reduce the composite outcome of hospitalisation, emergency department (ED) visits, or death, compared with placebo (RR 0.60, 95% CI 0.40–0.90.21). The incidence of all‐cause mortality (RR 1.00; 95% CI 0.06–15.91) and serious adverse events (RR 2.86; 95% CI 0.76–10.76) was also comparable between the two groups. Our meta‐analysis, with low to moderate certainty, found that metformin may provide modest benefit in reducing hospitalisation, ED visits, or mortality in patients with COVID‐19 without an association with increased serious adverse events. However, these findings should be interpreted cautiously, given the limited number of trials, low event rates, and clinical heterogeneity across studies. Further large RCTs are needed before metformin can be considered for use in COVID‐19.

Subjects

MeSH terms (MEDLINE)

MetforminCOVID-19 Drug TreatmentHypoglycemic AgentsHumansRandomized Controlled Trials as TopicHospitalizationSARS-CoV-2COVID-19Treatment Outcome

Author keywords

COVID‐19meta‐analysismetforminsystematic review

Substances

MetforminHypoglycemic Agents

Authors and institutions

  • Department of Medicine, Kuwait Teaching Hospital, Peshawar, Pakistan.
  • Department of Medicine, Nishtar Medical University, Multan, Pakistan.
  • Department of Medicine, Fatima Memorial College of Medicine and Dentistry, Lahore, Pakistan.
  • Department of Medicine, Punjab Medical College, Faisalabad, Pakistan.
  • Department of Medicine, Fauji Foundation Hospital, Rawalpindi, Pakistan.
  • Department of Medicine, People's University of Medical and Health Sciences, Nawabshah, Pakistan.

ORCID profiles: Muhammad Abubakr Siddique, Asma'a Munasar Ali Alsubari, Muhammad Ehsan, Jibran Ikram

Cite

APA

Tahir, T., Siddique, M. A., Ijaz, K., Nadeem, H., Rehman, A., Khan, S., Tarar, A. H., Lajwanti, Zafar, M. A. S., Raja, F., Jafar, U., Alsubari, A. M. A., Ehsan, M., & Ikram, J. (2026). Metformin for COVID‐19: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Reviews in Medical Virology. https://doi.org/10.1002/rmv.70172

Vancouver

Tahir T, Siddique MA, Ijaz K, Nadeem H, Rehman A, Khan S, et al. Metformin for COVID‐19: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Reviews in Medical Virology. 2026. doi:10.1002/rmv.70172

BibTeX
@article{Tahir2026,
  author = {Tahir, Taimoor and Siddique, Muhammad Abubakr and Ijaz, Khadija and Nadeem, Hania and Rehman, Abdur and Khan, Sameen and Tarar, Amna Humayun and Lajwanti and Zafar, Muhammad Ahmad Shujja and Raja, Fatima and Jafar, Uzair and Alsubari, Asma'a Munasar Ali and Ehsan, Muhammad and Ikram, Jibran},
  title = {Metformin for COVID‐19: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
  journal = {Reviews in Medical Virology},
  year = {2026},
  doi = {10.1002/rmv.70172}
}
Start for free →